N-lorem Foundation
Clinical trials sponsored by N-lorem Foundation, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Custom-Made genetic drug targets rare brain disease in first human test Results expected Nov 2026 (estimated)
- Custom drug targets rare genetic brain condition in one patient Results expected Feb 2027 (estimated)
- Custom drug targets rare genetic brain disease in First-Ever human test Results expected Feb 2027 (estimated)
- Custom Gene-Targeting drug offers hope for one child with fatal brain disorder Results expected Feb 2027 (estimated)
- Custom-Made genetic drug tested in single ALS patient Results expected Mar 2027 (estimated)
-
One-Patient trial aims to treat Ultra-Rare genetic disorder
Disease control Not yet recruitingThis study tests a custom-made drug called an antisense oligonucleotide (ASO) designed for one person with Schuurs-Hoeijmakers syndrome, a rare genetic condition. The drug aims to correct a specific genetic mutation to improve communication and motor skills. Only one participant …
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Custom-Made genetic drug tested in single ALS patient
Disease control Not yet recruitingThis study tests a custom-made drug designed for one person with ALS caused by a specific gene mutation (CHCHD10). The drug aims to slow disease progression by targeting the genetic root cause. The participant will be closely monitored for changes in muscle strength, breathing, a…
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC